Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart and Insulin Detemir.

The long-term safety and tolerability of insulin degludec (IDeg) was compared with that of insulin detemir (IDet), as basal treatment in participants with type 1 diabetes mellitus (T1DM).

IDeg was administered once daily, whilst IDet was administered once or twice daily depending on patients' glycaemic control.

Who Took Part

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In the present multinational, 26-week core + 26-week extension, controlled, open-label, parallel-group trial, adults with T1DM were randomized to IDeg or IDet as basal insulin treatment combined with meal-time bolus insulin aspart.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

The participants were allocated by chance, so the Insulin Aspart group and the comparison group should start out alike.

Nothing was hidden in this open-label Insulin Aspart study: the participants and staff both knew the treatment.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

The subject headings attached to it are Blood Glucose, Diabetes Mellitus, Type 1, Fasting, Glycated Hemoglobin, Hypoglycemia, Hypoglycemic Agents and Insulin Aspart.

Author keywords: basal-bolus, hypoglycaemia, insulin degludec, insulin detemir, insulin therapy and type 1 diabetes mellitus.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Insulin Aspart and Insulin Detemir.

The publication is from 2016 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Insulin Aspart compound page and the Insulin Detemir compound page.